DCM Advisors’s AbbVie ABBV Stock Holding History

DCM Advisors’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$7.15M	Buy	28,403 +799	+3%	+$172K	2.82%	20
2026 Q1	$6M	Sell	27,604 -234	-0.8%	-$51.9K	2.73%	19
2025 Q4	$6.36M	Hold	27,838	–	–	2.64%	18
2025 Q3	$6.45M	Sell	27,838 -77	-0.3%	-$15.7K	2.72%	17
2025 Q2	$5.18M	Buy	27,915 +2,059	+8%	+$383K	2.22%	21
2025 Q1	$5.41M	Sell	25,856 -3,017	-10%	-$587K	2.89%	15
2024 Q4	$5.13M	Buy	28,873 +1,078	+4%	+$198K	2.41%	17
2024 Q3	$5.49M	Hold	27,795	–	–	2.77%	16
2024 Q2	$4.77M	Sell	27,795 -4,486	-14%	-$743K	2.52%	19
2024 Q1	$5.88M	Sell	32,281 -7,804	-19%	-$1.34M	2.42%	18
2023 Q4	$6.21M	Buy	40,085 +5,447	+16%	+$794K	2.23%	19
2023 Q3	$5.16M	Sell	34,638 -949	-3%	-$139K	2.33%	18
2023 Q2	$4.79M	Buy	35,587 +488	+1%	+$71.6K	2.05%	18
2023 Q1	$5.59M	Sell	35,099 -263	-0.7%	-$40.2K	2.6%	16
2022 Q4	$5.71M	Buy	35,362 +13,725	+63%	+$2.1M	2.77%	15
2022 Q3	$2.9M	Sell	21,637 -377	-2%	-$54.1K	1.46%	14
2022 Q2	$3.37M	Buy	22,014 +1,040	+5%	+$159K	1.46%	12
2022 Q1	$3.4M	Sell	20,974 -220	-1%	-$32K	1.2%	18
2021 Q4	$2.87M	Buy	21,194 +9,910	+88%	+$1.17M	0.85%	29
2021 Q3	$1.22M	Buy	+11,284	New	+$1.29M	0.47%	56

Other funds holding ABBV

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

DCM Advisors's ABBV Position: Q2 2026 in Review

DCM Advisors increased its AbbVie (ABBV) stake by 2.9% in Q2 2026, buying an estimated $172K and bringing the position to 28,403 shares worth $7.15M. The position accounts for 2.82% of the portfolio, ranked #20.

DCM Advisors first reported a position in ABBV in Q3 2021 and has held it in 20 quarters since. 4,224 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

DCM Advisors held 28,403 shares of AbbVie worth $7.15M as of Q2 2026.
DCM Advisors bought 799 AbbVie shares in Q2 2026, an estimated $172K.
AbbVie made up 2.82% of DCM Advisors's portfolio in Q2 2026, its #20 holding.
DCM Advisors first reported a position in AbbVie in Q3 2021 and has held it in 20 quarters since.
4,224 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on DCM Advisors's 13F filing for Q2 2026, filed 13 Aug 2026.